These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15371985)

  • 1. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
    Niemi M; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2004 Sep; 76(3):239-49. PubMed ID: 15371985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.
    Park JY; Kim KA; Kang MH; Kim SL; Shin JG
    Clin Pharmacol Ther; 2004 Mar; 75(3):157-62. PubMed ID: 15001966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
    Tornio A; Niemi M; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2008 Jan; 36(1):73-80. PubMed ID: 17913794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.
    Niemi M; Kajosaari LI; Neuvonen M; Backman JT; Neuvonen PJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):441-7. PubMed ID: 15025742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
    Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
    Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.
    Villikka K; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1999 Apr; 65(4):377-81. PubMed ID: 10223773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
    Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects.
    Kim KA; Park PW; Kim HK; Ha JM; Park JY
    J Clin Pharmacol; 2005 Aug; 45(8):941-6. PubMed ID: 16027405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.
    Park JY; Kim KA; Shin JG; Lee KY
    Br J Clin Pharmacol; 2004 Oct; 58(4):397-402. PubMed ID: 15373932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.
    Kim KA; Park PW; Kim KR; Park JY
    Br J Clin Pharmacol; 2007 Mar; 63(3):339-45. PubMed ID: 16981900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rifampicin on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ
    Br J Clin Pharmacol; 2006 Jan; 61(1):70-8. PubMed ID: 16390353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.
    Hruska MW; Amico JA; Langaee TY; Ferrell RE; Fitzgerald SM; Frye RF
    Br J Clin Pharmacol; 2005 Jan; 59(1):70-9. PubMed ID: 15606443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifampin reduces plasma concentrations and effects of zolpidem.
    Villikka K; Kivistö KT; Luurila H; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Dec; 62(6):629-34. PubMed ID: 9433391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.
    Kyrklund C; Backman JT; Kivistö KT; Neuvonen M; Laitila J; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Dec; 68(6):592-7. PubMed ID: 11180018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
    Naik H; Wu JT; Palmer R; McLean L
    Br J Clin Pharmacol; 2012 Aug; 74(2):327-35. PubMed ID: 22242967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.
    Karonen T; Filppula A; Laitila J; Niemi M; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2010 Aug; 88(2):223-30. PubMed ID: 20592724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.
    Pedersen RS; Damkier P; Brosen K
    Br J Clin Pharmacol; 2006 Dec; 62(6):682-9. PubMed ID: 16856883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.
    Park JY; Kim KA; Park PW; Park CW; Shin JG
    Clin Pharmacol Ther; 2003 Oct; 74(4):334-40. PubMed ID: 14534520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
    Niemi M; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.